Form 4: Exelixis EVP, Commercial, Patrick J. Haley, Reports Stock Sale Under 10b5-1 Plan
SEC Form 4 Filing
Patrick J. Haley, EVP, Commercial at Exelixis, sold 14,000 shares of common stock at $25.50 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Patrick J. Haley, EVP, Commercial at Exelixis, filed a Form 4 disclosing changes in beneficial ownership.
- On August 7, 2024, Haley sold 14,000 shares of Exelixis common stock at a price of $25.50 per share.
- The sale was executed under a Rule 10b5-1 trading plan adopted on August 7, 2023.
- Following the transaction, Haley directly owns 341,036 shares of Exelixis common stock, which includes 239,572 shares issuable upon vesting of restricted stock units.
- Haley also indirectly owns 10,648 shares through a 401(k) plan and 23,539 shares through his spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was part of a pre-planned trading arrangement. It doesn't necessarily reflect a positive or negative view of the company's future.
Industry Context
Form 4 filings are a routine part of insider trading activity and are closely watched by investors for signals about management's view of the company's prospects. Sales under 10b5-1 plans are generally less informative since they are pre-arranged.
Comparison to Industry Standards
- Comparing Haley's transactions to those of other executives in similar biotech companies would require analyzing their Form 4 filings over a comparable period.
- It's common for executives to utilize 10b5-1 plans to diversify their holdings and manage personal finances, so this transaction is not necessarily indicative of a negative outlook for Exelixis.
- A deeper analysis would involve comparing the size and frequency of Haley's sales to those of peers at companies like Gilead, Amgen, or Biogen.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.
- There is no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 08/07/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 08/07/2024 | Date of transaction (stock sale) |
| 08/07/2024 | Date of 401(k) plan statement |
| 08/09/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.